Infections, allergies, autoimmune diseases, irritation, injuries, or damage to the eyes, eyelids, or surrounding tissues can cause eye inflammation. Depending on the source of the inflammation, different areas of the eye may be impacted. It is possible for eyes to get inflamed at any age. The kind and severity of the underlying disease, ailment, or condition will determine the duration of the eye inflammation and the course of treatment:
For diagnosis of eye inflammation include examination such as Assessment of vision, Tonometry, A slit-lamp examination, Ophthalmoscopy, etc. Medication for the treatment of eye inflammation include drugs that reduce inflammation such as a corticosteroid, drugs that control spasms, drugs that fight bacteria or viruses such as antibiotics or antivirals, drugs that affect the immune system or destroy cells, etc.
Global Eye Inflammation Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic is expected to hamper growth of the global eye inflammation treatment market, owing to restriction in the supply chain of drugs during the COVID-19 pandemic. For instance, according to data reported by United Nations Office on Drugs and Crime in July 2020, the effective measures taken to control the spread of COVID-19 pandemic has at the end badly affected to drug supply chain. Many countries across the world have reported an overall shortage of many types of drugs at the retail level. Supply chain affected the transport and production of all kind of drugs, which is expected to hamper the market of acute bacterial skin and skin structure infections.
Moreover, a decline in eye disease treatment during COVID-19 is expected to hamper the global eye inflammation treatment market growth. For instance, according to the data published in July 2020, in the Indian Journal of Ophthalmology, the COVID-19 pandemic has a huge negative impact on the working of eye-care hospitals. The lockdown has put a burden on patients, clinicians, staff, and the hospital management. COVID-19 pandemic and government-imposed restrictions have brought financial, logistic, and psychological challenges. This made reduction in visit of patient to eye clinics and hospitals this resulted into decline in eye treatment which is expected to hamper the growth of global eye inflammation treatment market.
The global eye inflammation treatment market is estimated to be valued at US$ 564.4 Mn in 2022 and is expected to exhibit a CAGR of 5.8% over the forecast period (2022-2030)
Figure 1: Global Eye Inflammation Treatment Market Share, (%), Analysis, By Drug Class,
Global Eye Inflammation Treatment Market Key Drivers
Increasing research and development by key market players for the development of new eye inflammation treatment is expected to drive the growth of global eye inflammation treatment market over the forecast period.
Market players are involved in research and development for the development of eye inflammation treatment is expected to drive the growth of global eye inflammation treatment market. For instance, on April 21, 2022, SALVAT, a manufacturer of sterile liquids pharmaceutical products, completed the phase III clinical trials of its ocular corticosteroid with clobetasol for the treatment of inflammation and pain in cataract surgery patients. To commercialize the new corticosteroid globally in the second half of 2023, the company has started the approval application processes with the U.S. Food and Drug Administration (FDA) and the European health authorities.
Increasing product launch by key market players, for the treatment of eye disease is expected to propel the growth of global eye inflammation treatment market, over the forecast period.
Key market players are launching product for the treatment of eye disease is expected to propel the growth of global eye infection treatment market. For instance, on January 10, 2022, NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, announced the launch of its AVENOVA Lubricant Eye drops. These eye drops are formulated to treat dry eye symptoms. Avenova is antimicrobial and uses pure 0.01% Hypochlorous Acid that fight with toxins and inflammation caused by bacteria.
|Base Year:||2021||Market Size in 2022:||US$ 564.4 Mn|
|Historical Data for:||2018 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||5.8%||2030 Value Projection:||US$ 888.5 Mn|
GSK plc., Alcon Laboratories Inc., Merck & Co. Inc., Alimera Sciences, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Akron Pharma Inc., Intas Pharmaceuticals Ltd., Amgen Inc., Sanofi S.A., Johnson & Johnson Services Inc., Pfizer Inc., Macleods Pharmaceuticals Ltd., Mylan N.V., Bausch Health Companies Inc.
|Restraints & Challenges:||
Global Eye Inflammation Treatment Market – Restraints
The side effects associated with the use of eye anti-inflammatory drugs is expected to hamper the growth of global eye inflammation treatment market. For instance, according to data published on July 01, 2022, by Mayo Foundation for Medical Education and Research, an academic medical center, eye anti-inflammatory drugs may sometime have side effects such as blurred vision or other change in vision, fever or chills, pain, bleeding in the eye, etc. which can become worse while using drugs. These side effects may stop during the treatment as body adjusts to the drugs or side effects can become worse which needed doctor attention.
Moreover, challenging manufacturing process is also expected to limit the market growth. Eye care product needs unique manufacturing process for making the product appropriately aligned with the GMP regulations for sterile products. Since the formulations are prone to get affected by the pathogens available in the environment, they are formulated under highly protected area.
Global Eye Inflammation Treatment Market – Regional Analysis
On the basis of region, the global eye inflammation treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa
Among regions, North America eye inflammation treatment market is expected to hold a dominant position during the forecast period, owing to increasing product approvals by regulatory authorities. For instance, on February 02, 2022, the U.S. Food and Drug Administration has approved the first generic version of Restasis, a cyclosporine ophthalmic emulsion, 0.05% single-use vials eye drops planned to boost tear production in patients whose tear production is thought to be suppressed because of ocular inflammation linked to keratoconjunctivitis sicca, a dry eye condition.
Furthermore, Europe is also estimated to witness significant growth in the global eye inflammation treatment market, owing to increasing recommendation by regulatory bodies of marketing of eye disease treatment drugs in Europe. For instance, in May 2017, The European Medicines Agency has recommended granting a marketing authorisation in the European Union for Oxervate, a cenegermin for the treatment of moderate or severe neurotrophic keratitis, an unusual eye disease that can lead to loss of sight.
Figure 2: Global Eye Inflammation Treatment Market (US$ Mn), by Region, 2022
Global Eye Inflammation Treatment Market – Competitive Landscape
Major players operating in the global eye Inflammation treatment market include GSK plc., Alcon Laboratories Inc., Merck & Co. Inc., Alimera Sciences, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Akron Pharma Inc., Intas Pharmaceuticals Ltd., Amgen Inc., Sanofi S.A., Johnson & Johnson Services Inc., Pfizer Inc., Macleods Pharmaceuticals Ltd., Mylan N.V., Bausch Health Companies Inc.
Eye inflammation, also known as ocular inflammation, is a disorder marked by the swelling of one or more eye regions and can be brought on by a number of different things, from minor irritation to specific illnesses. Eye Inflammation is classified according to the part of the eye that has been affected. Scleritis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, and Panuveitis are the different classifications. Panuveitis is a general word for an inflammation that affects the entire eye.
Eye inflammation is caused by various factors such as inflammatory diseases, injuries in the eye, microbial infections such as viral, bacterial, and fungal infection or exposure to certain toxic chemicals such as strong acids or pesticides.
Increasing prevalence of autoimmune disorders is also expected to benefit in growth of the global eye inflammation treatment market, over the forecast period. For instance, according to a study published in February 2019 by National Multiple Sclerosis Society, in the journal Neurology, in 2017, nearly 1 million adults were living with multiple sclerosis in the U.S. Multiple sclerosis is a disease that reasons inflammation and damage to the optic nerve that cases optic neuritis. Optic neuritis as an early sign of multiple sclerosis. Optic neuritis causes pain in eye, vision loss in one eye, etc. Steroid are used as a medication to reduce inflammation in the optic nerve, which is expected to drive the global eye inflammation market.
Moreover, advanced treatment of eye disease is expected to propel the growth of global eye inflammation treatment market, over the forecast period. For instance, according to data published on November 04, 2021, by American Academy of Ophthalmology, new dry eye treatments may be more effective than existing ones. Modern treatments for eye disease include lifestyle changes, a nasal spray, punctual plugs, anti-inflammatory medications, deep-cleaning devices, and specialized contact lenses. Currently available medications for the treatment of dry eye disease, approved by the U.S. Food and Drug Administration are Tyrvaya, Restasis, Cequa, Xiidra and Eysuvis.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.